Hi Robert,

In response to your question about Pluristem, which you posted on the Sinovac Investors' Group message board; you are correct, I cannot comment on any market activity for the companies I represent or have recently represented.

Based on what I know, I will say that Pluristem is in very good shape fundamentally. I am very impressed with Zami's ability to accomplish so much and indicative of what he will do with Pluristem in the future.  Here is a quick run down of recent accomplishments:

May

Acquired the Patents and Technology for the Three Dimensional Expansion of Human Cells – this is the core technology for Pluristem's future products

Closed on $13.5 Million Private Equity Investment

Listed on Frankfurt Stock Exchange

Announced invitation to Present Two Scientific Posters at the International Society for Cellular Therapy – this will occur June 24-27, 2007 in Sydney Australia (http://www.celltherapysociety.org/)

April

Received $1.1 Million from Exercise of Warrants – I expect that more have been exercised since this was announced.

March

Began Upgrading Its Manufacturing Facility to Support $200 Million in Production Capacity for PLX - I

Announced Evidence That PLX Cells Are Immunosuppressive – this is a key Scientific Advance in Stem Cell Research and complimentary to the evidence that PLX-I cells are also Immune Priviledged

February

Announced First Licensing Agreement and Stock Swap With Stem Cell Innovations, Inc. – The key point to this agreement is that Pluristem's PLX-I product can be marketed in areas of the world that management would prefer to not concentrate on (Asia, excluding Japan).  This enables Pluristem to focus its marketing on the Americas; Europe; Middle East; etc.

Announced US FDA Acceptance of its Pre-IND Application to begin Pre-clinical Studies using PLX- I in Hematological Malignancies

Announced Evidence That PLX-I Cells Are Immune Privileged

And the achievements go on and on. I will add that the tempo of their business and R&D achievements are increasing and I anticipate they will continue to do so since they have more money to execute their business strategy.

Respectfully,